SKP alleviates the ferroptosis in diabetic kidney disease through suppression of HIF-1α/HO-1 pathway based on network pharmacology analysis and experimental validation.

导出 OA

翻译打印收藏纠错

第一作者： Yangtian,Yan

第一单位： School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.

作者： Yangtian,Yan ^[1] ; Ningning,Yuan ^[1] ; Yuchi,Chen ^[1] ; Yun,Ma ^[2] ; Ali,Chen ^[3] ; Fujing,Wang ^[1] ; Shihua,Yan ^[1] ; Zhuo'en,He ^[1] ; Jinyue,He ^[1] ; Chi,Zhang ^[1] ; Hao,Wang ^[1] ; Mingqing,Wang ^[4] ; Jianxin,Diao ^[5] ; Wei,Xiao ^[6]

作者单位： School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. ^[1] Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. ^[2] Center for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. ^[3] School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. mingqing@smu.edu.cn. ^[4] School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. jianxindiao@163.com. ^[5] School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. xw7688@smu.edu.cn.;Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. xw7688@smu.edu.cn. ^[6]

关键词 Diabetic kidney disease (DKD)Ferroptosis HIF-1α/HO-1 signaling pathway Network pharmacology Shenkang pills (SKP)

DOI 10.1186/s13020-024-00901-5

PMID 38403669

发布时间 2024-02-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交